These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917 [TBL] [Abstract][Full Text] [Related]
4. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Peyrin-Biroulet L; Laclotte C; Bigard MA Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600 [TBL] [Abstract][Full Text] [Related]
5. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. Salar A; Bessa X; Muñiz E; Monfort D; Besses C; Andreu M Gut; 2007 Aug; 56(8):1169-70. PubMed ID: 17344276 [No Abstract] [Full Text] [Related]
6. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab. Gupta A; Pendyala P; Arora P; Sitrin MD J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576 [TBL] [Abstract][Full Text] [Related]
7. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab. Moss AC; Treister NS; Marsee DK; Cheifetz AS Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307 [No Abstract] [Full Text] [Related]
8. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808 [TBL] [Abstract][Full Text] [Related]
9. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. Casanova MJ; Chaparro M; Valenzuela C; Cisneros C; Gisbert JP World J Gastroenterol; 2015 Feb; 21(7):2260-2. PubMed ID: 25717268 [TBL] [Abstract][Full Text] [Related]
10. Aortic thrombosis in young women with Crohn's disease receiving adalimumab: report of two cases. Leblanc S; Lloret Linares C; Cacheux W; Mouthon L; Chaussade S Inflamm Bowel Dis; 2011 Mar; 17(3):862-3. PubMed ID: 20629181 [No Abstract] [Full Text] [Related]
11. First case report of adalimumab-induced psoriasis in Crohn's disease. Harris MD; Richards R Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532 [No Abstract] [Full Text] [Related]
12. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease. Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411 [TBL] [Abstract][Full Text] [Related]
13. Psoriasiform Skin Lesions Are Caused by Both Infliximab and Adalimumab in a Patient with Crohn's Disease. Cankurtaran E; Ekiz F; Hamamci M; Akinci H; Coskun Y; Yuksel I Dig Dis Sci; 2016 Apr; 61(4):1206-7. PubMed ID: 26894400 [No Abstract] [Full Text] [Related]
14. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Mishkin DS; Van Deinse W; Becker JM; Farraye FA Inflamm Bowel Dis; 2006 Aug; 12(8):827-8. PubMed ID: 16917239 [No Abstract] [Full Text] [Related]
15. Acute lymphoid leukemia in a Crohn's disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids. Cesarini M; Vernia P; Angelucci E Inflamm Bowel Dis; 2010 Mar; 16(3):371-2. PubMed ID: 19637388 [No Abstract] [Full Text] [Related]
16. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Jürgens M; Brand S; Filik L; Hübener C; Hasbargen U; Beigel F; Tillack C; Göke B; Ochsenkühn T; Seiderer J Inflamm Bowel Dis; 2010 Oct; 16(10):1634-6. PubMed ID: 20027647 [No Abstract] [Full Text] [Related]
17. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab. Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289 [No Abstract] [Full Text] [Related]
18. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease. Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783 [TBL] [Abstract][Full Text] [Related]
19. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies]. Jałocha Ł; Wojtuń S; Wojtkowiak M; Błaszak A; Dyrla P; Gil J Pol Merkur Lekarski; 2009 May; 26(155):491-2. PubMed ID: 19606707 [TBL] [Abstract][Full Text] [Related]
20. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA J Crohns Colitis; 2012 Feb; 6(1):108-11. PubMed ID: 22261535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]